Jacqueline A Shaw

List of Publications by Year in Descending Order

95 papers	7,174 citations	37 h-index	84 g-index
106 ext. papers	8,953 ext. citations	9.7 avg, IF	4.96 L-index

#	Paper	IF	Citations
95	Cell-free DNA analysis in current cancer clinical trials: a review.. *British Journal of Cancer*, **2022**,	8.7	9
94	Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure. *European Journal of Preventive Cardiology*, **2021**, 28, e28-e31	3.9	5
93	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. *JCO Precision Oncology*, **2021**, 5,	3.6	2
92	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-**B**. *Oncogene*, **2021**, 40, 1077-1090	9.2	9
91	Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. *Nature Communications*, **2021**, 12, 1751	17.4	20
90	Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. *Annals of Oncology*, **2021**, 32, 681-684	10.3	3
89	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. *Breast Cancer Research and Treatment*, **2021**, 188, 465-476	4.4	0
88	Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays. *Annals of Oncology*, **2021**, 32, 1057-1060	10.3	0
87	Using DNA sequencing data to quantify T cell fraction and therapy response. *Nature*, **2021**, 597, 555-560	50.4	5
86	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. *Cell Reports*, **2020**, 31, 107550	10.6	19
85	A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. *Scientific Reports*, **2020**, 10, 4553	4.9	11
84	The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
83	Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis. *British Journal of Cancer*, **2020**, 122, 1077-1084	8.7	7
82	Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. *British Journal of Cancer*, **2020**, 123, 1271-1279	8.7	12
81	Detection of Breast Cancer ESR1 p.E380Q Mutation on an ISFET Lab-on-Chip Platform **2020**,		3
80	The liquid biopsy: towards standardisation in preparation for prime time. *Lancet Oncology, The*, **2019**, 20, 758-760	21.7	14
79	Opportunities and challenges of circulating biomarkers in neuroblastoma. *Open Biology*, **2019**, 9, 190056	7	14

78	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. *Clinical Cancer Research*, **2019**, 25, 4255-4263	12.9	133
77	Early detection of pre-malignant lesions in a KRAS-driven mouse lung cancer model by monitoring circulating free DNA. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	10
76	Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. *Breast Cancer Research*, **2019**, 21, 149	8.3	40
75	A framework for the development of effective anti-metastatic agents. *Nature Reviews Clinical Oncology*, **2019**, 16, 185-204	19.4	119
74	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. *Cancer Cell*, **2018**, 33, 649-663.e4	24.3	296
73	Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. *Heliyon*, **2018**, 4, e00699	3.6	61
72	Integrating next generation sequencing into the clinic. *Pathology*, **2018**, 50, S30-S31	1.6	
71	Circulating tumour-derived DNA in metastatic soft tissue sarcoma. *Oncotarget*, **2018**, 9, 10549-10560	3.3	22
70	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. *Cell Death and Disease*, **2018**, 9, 894	9.8	19
69	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. *Clinical Cancer Research*, **2017**, 23, 88-96	12.9	151
68	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. *Clinical Chemistry*, **2017**, 63, 532-541	5.5	60
67	Telomere maintenance in soft tissue sarcomas. *Journal of Clinical Pathology*, **2017**, 70, 371-377	3.9	1
66	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. *Immunity*, **2017**, 46, 577-586	32.3	225
65	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature*, **2017**, 545, 446-451	50.4	796
64	Tracking the Evolution of Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2017**, 376, 2109-2121	59.2	1156
63	The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. *Expert Review of Molecular Diagnostics*, **2017**, 17, 459-470	3.8	9
62	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. *Cell*, **2017**, 171, 1259-1271.e11	56.2	541
61	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. *BMC Cancer*, **2017**, 17, 697	4.8	77

60	Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. *Oncotarget*, **2017**, 8, 87221-87233	3.3	29
59	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 479-91	12.9	13
58	The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. *Expert Review of Molecular Diagnostics*, **2016**, 16, 751-5	3.8	15
57	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. *Oncogene*, **2015**, 34, 2103-14	9.2	11
56	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. *Clinical Chemistry*, **2015**, 61, 974-82	5.5	129
55	The pioneer factor PBX1 is a novel driver of metastatic progression in ER□positive breast cancer. *Oncotarget*, **2015**, 6, 21878-91	3.3	28
54	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. *Breast Cancer Research and Treatment*, **2014**, 147, 295-309	4.4	9
53	The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy. *Future Oncology*, **2014**, 10, 2555-60	3.6	2
52	Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. *PLoS Biology*, **2014**, 12, e1001906	9.7	136
51	Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. *PLoS ONE*, **2014**, 9, e115346	3.7	13
50	NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. *Breast Cancer Research and Treatment*, **2014**, 148, 581-90	4.4	62
49	Circulating free DNA in the management of breast cancer. *Annals of Translational Medicine*, **2014**, 2, 3	3.2	16
48	Genomic instability in pre-neoplastic colonic lesions. *Oncogene*, **2013**, 32, 5331-2	9.2	
47	Hide and seek: tell-tale signs of breast cancer lurking in the blood. *Cancer and Metastasis Reviews*, **2013**, 32, 289-302	9.6	13
46	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). *Annals of Oncology*, **2013**, 24, 924-30	10.3	11
45	LMTK3 is implicated in endocrine resistance via multiple signaling pathways. *Oncogene*, **2013**, 32, 3371-80	9.2	34
44	Influence of plasma processing on recovery and analysis of circulating nucleic acids. *PLoS ONE*, **2013**, 8, e77963	3.7	134
43	Determination of Breast Cancer Dormancy: Analysis of Circulating Free DNA Using SNP 6.0 Arrays **2013**, 35-50		

42	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. *Nucleic Acids Research*, **2012**, 40, e82	20.1	283
41	Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. *Genome Research*, **2012**, 22, 220-31	9.7	152
40	The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. *British Journal of Cancer*, **2012**, 106, 375-82	8.7	13
39	Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. *Biomarkers in Medicine*, **2011**, 5, 87-91	2.3	23
38	Detection of HER2 amplification in circulating free DNA in patients with breast cancer. *British Journal of Cancer*, **2011**, 104, 1342-8	8.7	68
37	Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. *Breast Cancer Research*, **2010**, 12, R57	8.3	23
36	Expression of tenascin-C and its isoforms in the breast. *Cancer and Metastasis Reviews*, **2010**, 29, 595-606	9.6	33
35	Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. *Breast Cancer Research*, **2009**, 11, R24	8.3	91
34	Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. *Cancer Research*, **2008**, 68, 7760-8	10.1	55
33	Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. *Annals of the New York Academy of Sciences*, **2008**, 1137, 98-107	6.5	80
32	Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. *Clinical Cancer Research*, **2007**, 13, 6673-80	12.9	45
31	Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. *Breast Cancer Research*, **2007**, 9, R67	8.3	40
30	Alpha-tocopherol supplementation does not affect monocyte endothelial adhesion or C-reactive protein levels but reduces soluble vascular adhesion molecule-1 in the plasma of healthy subjects. *Redox Report*, **2006**, 11, 214-22	5.9	6
29	The importance of careful blood processing in isolation of cell-free DNA. *Annals of the New York Academy of Sciences*, **2006**, 1075, 313-7	6.5	58
28	Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene. *Oncogene*, **2004**, 23, 3434-43	9.2	19
27	Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. *Journal of Pathology*, **2003**, 201, 562-72	9.4	184
26	Vitamin C supplementation in normal subjects reduces constitutive ICAM-1 expression. *Biochemical and Biophysical Research Communications*, **2003**, 308, 339-45	3.4	37
25	Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. *International Journal of Cancer*, **2002**, 98, 205-9	7.5	35

24	Evidence that superficial basal cell carcinoma is monoclonal from analysis of the Ptch1 gene locus. *British Journal of Dermatology*, **2002**, 147, 931-5	4	15
23	Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. *Journal of Pathology*, **2002**, 198, 450-7	9.4	82
22	Effects of oral vitamin C on monocyte: endothelial cell adhesion in healthy subjects. *Biochemical and Biophysical Research Communications*, **2002**, 294, 1161-8	3.4	26
21	Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. *Journal of Clinical Pathology*, **2001**, 54, 300-6		34
20	Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. *Oncogene*, **2001**, 20, 1509-18	9.2	318
19	Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. *British Journal of Surgery*, **2000**, 87, 1569-75	5.3	55
18	Inactive matrix metalloproteinase 2 is a normal constituent of human glomerular basement membrane. An immuno-electron microscopic study. *Journal of Pathology*, **2000**, 191, 61-6	9.4	8
17	Expression of oestrogen receptor alpha variants in non-malignant breast and early invasive breast carcinomas. *Journal of Pathology*, **2000**, 192, 159-65	9.4	12
16	Microsatellite alterations plasma DNA of primary breast cancer patients. *Clinical Cancer Research*, **2000**, 6, 1119-24	12.9	57
15	Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. *Nephrology Dialysis Transplantation*, **1999**, 14, 1234-7	4.3	97
14	Microsatellite instability in ductal carcinoma in situ of the breast. *Journal of Pathology*, **1998**, 185, 18-24	9.4	28
13	Reproducibility in the quantification of mRNA levels by RT-PCR-ELISA and RT competitive-PCR-ELISA. *BioTechniques*, **1998**, 24, 652-8	2.5	66
12	Numerical chromosomal aberrations in Hodgkin's disease detected by in situ hybridisation on routine paraffin sections. *Journal of Clinical Pathology*, **1997**, 50, 553-8	3.9	5
11	Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. *British Journal of Cancer*, **1997**, 75, 1324-9	8.7	60
10	Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. *British Journal of Cancer*, **1997**, 76, 1558-61	8.7	50
9	Molecular pathology of breast cancer and its application to clinical management. *Cancer and Metastasis Reviews*, **1997**, 16, 5-27	9.6	45
8	Amplification of specific mRNA from a single human renal glomerulus, with an approach to the separation of epithelial cell mRNA. *Journal of Pathology*, **1996**, 180, 188-93	9.4	20
7	Microsatellite instability in early sporadic breast cancer. *British Journal of Cancer*, **1996**, 73, 1393-7	8.7	61

6	AMPLIFICATION OF SPECIFIC mRNA FROM A SINGLE HUMAN RENAL GLOMERULUS, WITH AN APPROACH TO THE SEPARATION OF EPITHELIAL CELL mRNA **1996**, 180, 188		2
5	Identification of CpG islands in a physical map encompassing the Friedreich's ataxia locus. *Genomics* , **1991**, 9, 90-5	4.3	23
4	"Acadian" and "classical" forms of Friedreich ataxia are most probably caused by mutations at the same locus. *American Journal of Medical Genetics Part A*, **1989**, 33, 266-8		34
3	Mapping of mutation causing Friedreich's ataxia to human chromosome 9. *Nature*, **1988**, 334, 248-50	50.4	297
2	Exclusion of the Friedreich ataxia gene from chromosome 19. *Human Genetics*, **1987**, 76, 186-90	6.3	6
1	Peptide nucleic acid clamping to improve the sensitivity of Ion Torrent-based detection of an oncogenic mutation in KRAS. *Matters*,	0	3